This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Chengdu Yiping Medical Science & Technology Co. Ltd, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences Pla China. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Innovations of Xiaoyu Xu in the Field of Medical Science
Introduction
Xiaoyu Xu is a notable inventor based in Beijing, China. He has made significant contributions to the field of medical science, particularly in the development of innovative therapeutic agents. His work focuses on enhancing the efficacy of treatments related to diabetes and other metabolic disorders.
Latest Patents
Xiaoyu Xu holds a patent for "Site-directed PEG-modified exendin-4 analogs and uses thereof." This patent discloses PEG-modified Exendin-4 analogs, which are designed to improve the treatment of diseases associated with decreased activity of GLP-1 receptors, such as type II diabetes. The patent details methods for preparing these analogs and their pharmaceutical applications, highlighting their potential in preventing and treating related symptoms.
Career Highlights
Throughout his career, Xiaoyu Xu has worked with esteemed organizations, including the Institute of Pharmacology and Toxicology at the Academy of Military Medical Sciences in China and Chengdu Yiping Medical Science & Technology Co. Ltd. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.
Collaborations
Xiaoyu Xu has collaborated with notable colleagues, including Keliang Liu and Yuanjun Liang. These partnerships have fostered a collaborative environment that enhances the development of innovative medical solutions.
Conclusion
Xiaoyu Xu's contributions to medical science through his innovative patents and collaborations underscore his role as a leading inventor in the field. His work continues to pave the way for advancements in diabetes treatment and related health issues.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile